Growth In Two Different Markets
Today we’re looking at two businesses turning growing demand into higher revenue. One is bringing an approved cancer treatment to more patients. The other protects businesses as they expand their use of AI and cloud computing.
Both companies raised their latest full-year outlooks, while their shares pulled back in Tuesday’s session. Their current technical setups put them on our trading list, giving us an opportunity to seek bullish exposure after those declines.
Our first idea comes from Multibaggers, the group of outside analysts we follow who’ve identified multiple stocks that gained 100% or more. The second comes from Portfolio Armor’s Top Names. We checked both stocks’ technical setups using Chartmill.
The Appeal Of Asymmetric Upside
Options let us aim for a much larger percentage gain than the underlying stock’s gain. Our first trade leaves the potential upside uncapped, with $800 at risk at our maximum entry price before fees. Selling shorter-dated calls helps pay for longer-dated calls, while retaining exposure to a substantial rally.
Our second trade pays us $175 to open it. A stock gain of roughly one-third by expiration would produce a maximum profit of $1,175—about 142% of the $825 at risk, before fees. If the stock finishes flat or down 10% from Tuesday’s close, we keep the initial $175 credit.
Below, we explain why each company made the cut and show the exact options to buy and sell, the entry prices we’re willing to accept, and our plan for taking profits. You’ll have the entry and exit instructions up front, with follow-up guidance as the positions develop.
New to our alerts? “Start Here” explains how we select trades, set entry prices and exits, and track every completed result.
Today’s Multibaggers Trade
Theme: Expanding access to cancer treatment.
RSI: 53 · Technical: 9/10 · Setup: 6/10 · Fundamental: 5/10
